Quantinno Capital Management LP Acquires 251,573 Shares of Revvity Inc. $RVTY

Quantinno Capital Management LP grew its holdings in Revvity Inc. (NYSE:RVTY) by 449.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 307,511 shares of the company’s stock after purchasing an additional 251,573 shares during the period. Quantinno Capital Management LP’s holdings in Revvity were worth $26,941,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in RVTY. SummitTX Capital L.P. purchased a new stake in shares of Revvity during the first quarter valued at $1,009,000. Healthcare of Ontario Pension Plan Trust Fund increased its stake in Revvity by 58.9% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 7,122 shares of the company’s stock worth $624,000 after buying an additional 2,641 shares during the period. Public Employees Retirement System of Ohio increased its stake in Revvity by 33.4% in the 1st quarter. Public Employees Retirement System of Ohio now owns 98,237 shares of the company’s stock worth $8,607,000 after buying an additional 24,591 shares during the period. Bank of Nova Scotia lifted its holdings in Revvity by 436.4% during the 1st quarter. Bank of Nova Scotia now owns 58,546 shares of the company’s stock valued at $5,129,000 after buying an additional 47,631 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in Revvity by 82.7% during the 1st quarter. Sei Investments Co. now owns 703,406 shares of the company’s stock valued at $61,625,000 after buying an additional 318,368 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on RVTY. Evercore reissued an “outperform” rating and issued a $125.00 price objective on shares of Revvity in a research report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Finally, Stifel Nicolaus dropped their price objective on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Revvity currently has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Stock Down 0.7%

NYSE:RVTY opened at $112.79 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $118.30. The company has a 50-day moving average of $106.51 and a 200 day moving average of $99.91. The firm has a market cap of $12.58 billion, a PE ratio of 53.96, a price-to-earnings-growth ratio of 2.23 and a beta of 1.09.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The business had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. During the same quarter last year, the firm posted $1.01 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, research analysts anticipate that Revvity Inc. will post 5.25 EPS for the current fiscal year.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.